Relative risk of treatment-related mortality, disease-free survival, and relapse after blood stem cell transplantation compared with bone marrow transplantation for leukemia
| Outcome . | Patient group . | No. of patients . | RR5-150 [blood vs marrow] (95% CI) . | P value . | Adjusted 1-y probabilities, % (95% CI) . | ||
|---|---|---|---|---|---|---|---|
| Blood . | Bone marrow . | Blood . | Bone marrow . | ||||
| TRM5-151,5-152,5-160 | AL, CR1 | 112 | 204 | 0.59 (0.33-1.07) | .25 | 18 (11-26) | 28 (21-35) |
| AL, CR2 | 38 | 45 | 0.36 (0.13-0.99) | .04 | 13 (5-26) | 30 (16-44) | |
| CML, CP | 92 | 214 | 1.33 (0.82-2.15) | .27 | 37 (25-49) | 27 (19-32) | |
| CML, AP | 27 | 29 | 0.28 (0.12-0.67) | .004 | 26 (10-46) | 67 (37-85) | |
| TF/LFS5-151,5-153,5-160 | AL, CR1 | 82 | 181 | 0.76 (0.48-1.21) | .25 | 70 (56-80) | 61 (52-68) |
| AL, CR2 | 28 | 40 | 0.40 (0.18-0.92) | .03 | 77 (57-88) | 57 (40-71) | |
| CML, CP | 78 | 211 | 1.30 (0.82-2.08) | .27 | 63 (49-74) | 74 (66-80) | |
| CML, AP | 27 | 29 | 0.29 (0.14-0.59) | .0006 | 68 (45-84) | 23 (9-40) | |
| Relapse5-151,5-154,5-160 | AL, CR1 | 112 | 204 | 0.57 (0.04-7.66) | .67 | 14 (7-23) | 11 (7-17) |
| AL, CR2 | 38 | 45 | 0.24 (0.01-4.42) | .34 | 8 (2-20) | 13 (4-26) | |
| CML, CP | 92 | 214 | 0.48 (0.01-56.97) | .76 | 2 (1-8) | 1 (0.5-3) | |
| CML, AP | 27 | 29 | 1.02 (0.07-14.99) | .99 | 13 (3-30) | 21 (8-38) | |
| Outcome . | Patient group . | No. of patients . | RR5-150 [blood vs marrow] (95% CI) . | P value . | Adjusted 1-y probabilities, % (95% CI) . | ||
|---|---|---|---|---|---|---|---|
| Blood . | Bone marrow . | Blood . | Bone marrow . | ||||
| TRM5-151,5-152,5-160 | AL, CR1 | 112 | 204 | 0.59 (0.33-1.07) | .25 | 18 (11-26) | 28 (21-35) |
| AL, CR2 | 38 | 45 | 0.36 (0.13-0.99) | .04 | 13 (5-26) | 30 (16-44) | |
| CML, CP | 92 | 214 | 1.33 (0.82-2.15) | .27 | 37 (25-49) | 27 (19-32) | |
| CML, AP | 27 | 29 | 0.28 (0.12-0.67) | .004 | 26 (10-46) | 67 (37-85) | |
| TF/LFS5-151,5-153,5-160 | AL, CR1 | 82 | 181 | 0.76 (0.48-1.21) | .25 | 70 (56-80) | 61 (52-68) |
| AL, CR2 | 28 | 40 | 0.40 (0.18-0.92) | .03 | 77 (57-88) | 57 (40-71) | |
| CML, CP | 78 | 211 | 1.30 (0.82-2.08) | .27 | 63 (49-74) | 74 (66-80) | |
| CML, AP | 27 | 29 | 0.29 (0.14-0.59) | .0006 | 68 (45-84) | 23 (9-40) | |
| Relapse5-151,5-154,5-160 | AL, CR1 | 112 | 204 | 0.57 (0.04-7.66) | .67 | 14 (7-23) | 11 (7-17) |
| AL, CR2 | 38 | 45 | 0.24 (0.01-4.42) | .34 | 8 (2-20) | 13 (4-26) | |
| CML, CP | 92 | 214 | 0.48 (0.01-56.97) | .76 | 2 (1-8) | 1 (0.5-3) | |
| CML, AP | 27 | 29 | 1.02 (0.07-14.99) | .99 | 13 (3-30) | 21 (8-38) | |
CI indicates confidence interval; RR, relative risk; TRM, treatment-related mortality; AL, acute leukemia; CR1, 1st complete remission; CR2, 2nd complete remission; CML, chronic myelogenous leukemia; CP, chronic phase; AP, accelerated phase; and TF/LFS; treatment failure/leukemia-free survival.
Relative risks under 1.00 indicate a benefit for blood stem cell transplantation (lower risk of adverse outcome); relative risks greater than 1.00 indicate an adverse effect of blood stem cell transplantation (higher risk of adverse outcome).
Model stratified on the use of granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor.
Other significant variables were a Karnofsky performance score of 90 or higher (RR, 0.64; P = .01) and age 40 years or older (RR, 1.52; P = .006).
Other significant variables were a Karnofsky performance score of 90 or higher (RR, 0.64; P = .003) and age 40 years or older (RR, 1.33; P = .03).
No other significant variables.
No significant center effect.